Mitra-Majumdar M, Kesselheim AS - PLOS Medicine
The authors assess progress in addressing reporting bias in clinical trials noting that while regulatory requirements like ClinicalTrials.gov have improved transparency, studies still find that published literature overstates drug efficacy compared with FDA analyses.
VIEW SOURCE
Daval CJR, Kesselheim AS - STAT
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
Avorn J - MedPage Today